Research
Hormonal
Chronic low-grade inflammation (inflammaging) drives vascular aging by promoting oxidative stress, endothelial dysfunction, and atherosclerosis through the upregulation of cytokines like TNF-alpha and NF-kB activation.
Chronic, low-grade inflammation is a major driver of heart disease in older adults. It damages blood vessels by promoting oxidative stress and cell death. Managing inflammation through lifestyle factors is a key strategy for preventing age-related vascular disease.
StrongSupportsVERY_HIGH confidence
Abundant experimental and clinical data show that aging is associated with chronic low-grade inflammation (34), which predisposes the vasculature to the development of atherosclerosis... High levels of inflammatory cytokines contribute to a proinflammatory microenvironment that facilitates both the development of vascular dysfunction (42, 43) and promotes endothelial apoptosis in aging (21, 42).
Why this rating
Supported by abundant experimental and clinical data, including human plasma marker correlations.
Source
Mechanisms of Vascular Aging: New Perspectives
Zoltán Ungvári et al. · The Journals of Gerontology Series A · 2010
DOI 10.1093/gerona/glq113
narrative_reviewCited 526×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Regular aerobic exercise reverses age-related endothelial progenitor cell (EPC) dysfunction by increasing both the number and migratory activity of EPCs in older adults.Good
- Growth hormone (GH) and Insulin-like Growth Factor-1 (IGF-1) supplementation improves cardiovascular health by attenuating mitochondrial oxidative stress, upregulating antioxidant enzymes, and preserving endothelial progenitor cell function.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →